Drugs
NDA Approvals by Therapeutic Potential and Chemical Type
Year |
Therapeutic Potential - Priority Review* |
Therapeutic Potential - Standard Review** |
Total Approvals |
||||||||||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | Total | 1 | 2 | 3 | 4 | 5 | 6 |
7 |
Total | ||
1990 | 12 | 0 | 8 | 0 | 0 | 0 | 0 | 20 | 11 | 2 | 23 | 2 | 2 | 4 | 0 | 44 | 64 |
1991 | 14 | 0 | 5 | 0 | 0 | 0 | 0 | 19 | 16 | 1 | 15 | 2 | 10 | 0 | 0 | 44 | 63 |
1992 | 11 | 0 | 5 | 0 | 1 | 0 | 0 | 17 | 15 | 1 | 30 | 5 | 21 | 1 | 1 | 74 | 91 |
1993 | 13 | 0 | 6 | 0 | 0 | 0 | 0 | 19 | 12 | 0 | 18 | 1 | 18 | 2 | 0 | 51 | 70 |
1994 | 13 | 0 | 4 | 0 | 0 | - | 0 | 17 | 9 | 0 | 23 | 5 | 8 | - | 0 | 45 | 62 |
1995 | 9 | 1 | 5 | 0 | 0 | - | 0 | 15 | 19 | 5 | 30 | 2 | 11 | - | 0 | 67 | 82 |
1996 | 18 | 0 | 10 | 0 | 1 | - | 0 | 29 | 35 | 5 | 50 | 4 | 7 | - | 1 | 102 | 131 |
1997 | 9 | 1 | 6 | 1 | 3 | - | 0 | 20 | 30 | 2 | 52 | 12 | 4 | - | 1 | 101 | 121 |
1998 | 16 | 0 | 9 | 0 | 0 | - | 0 | 25 | 14 | 0 | 46 | 4 | 0 | - | 1 | 65 | 90 |
1999 | 19 | 1 | 7 | 1 | 0 | - | 0 | 28 | 16 | 2 | 32 | 3 | 2 | - | 0 | 55 | 83 |
2000 | 9 | 1 | 9 | 1 | 0 | - | 0 | 20 | 18 | 0 | 48 | 7 | 3 | - | 2 | 78 | 98 |
2001 | 7 | 1 | 1 | 0 | 1 | - | 0 | 10 | 17 | 1 | 23 | 9 | 5 | - | 1 | 56 | 66 |
2002 | 7 | 0 | 3 | 1 | 0 | - | 0 | 11 | 10 | 2 | 44 | 5 | 6 | - | 0 | 67 | 78 |
2003 | 9 | 0 | 4 | 1 | 0 | - | 0 | 14 | 12 | 5 | 31 | 7 | 3 | - | 0 | 58 | 72 |
2004 | 17 | 0 | 4 | 1 | 3 | - | 0 | 25 | 14 | 1 | 59 | 5 | 8 | - | 1 | 88 | 113 |
*Priority Review - Significant improvement compared to marketed products in the treatment, diagnosis, or prevention of a disease.
**Standard Review - The drug appears to have therapeutic qualities similar to those of one or more already marketed drugs.
***Chemical Types: |
Updated through 12/31/2004